Ethanol is a frequently abused drug that impairs cognitive processes such as learning. Varenicline, an a4b2 nicotinic receptor partial agonist and a7 nicotinic receptor full agonist prescribed for smoking cessation, has been shown to decrease ethanol consumption. The current study investigated whether varenicline could ameliorate ethanol-induced deficits in learning and whether varenicline alters blood alcohol concentration in C57BL/6 mice. Conditioning consisted of two auditory conditioned stimulus (CS; 30 s, 85 dB white noise)-foot shock unconditioned stimulus (US; 2 s, 0.57 mA) pairings. For all studies, saline or ethanol (1.0, 1.5, 2.0 g/kg i.p.) was administered 15 min before training, and saline or varenicline (0.05, 0.1, 0.2 mg/kg i.p.) was administered 60 min before either training or testing. For blood alcohol analysis, saline or varenicline (0.1 mg/kg) was administered 60 min before collection, and saline or ethanol (1.0, 1.5, 2.0 g/kg) was administered 15 min before collection. Varenicline dose-dependently ameliorated ethanol-induced conditioning deficits for all three doses of ethanol when administered before training but not when administered 24 h later, before testing. In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes.
Introduction
Although the health risks associated with alcohol abuse and addiction are well-known, alcoholism remains a worldwide public health issue. The most common alcohol abstinence aids for patients are nonspecific opioid receptor antagonists such as naltrexone (Nava, Premi, Manzato, & Lucchini, 2006) , and the glutamate receptor antagonist acamprosate, both of which decrease ethanol craving (Cowen, Adams, Kraehenbuehl, Vengeliene, & Lawrence, 2005) . Although these drugs, alone and in combination, decrease the likelihood of relapse to drinking in abstinent alcoholics (Feeney, Connor, Young, Tucker, & McPherson, 2006) , acamprosate has minimal effects on the cognitive deficits associated with acute and chronic ethanol consumption (Brasser, McCaul, & Houtsmuller, 2004) , while naltrexone actually exacerbates ethanol-induced cognitive deficits (McCaul, Wand, Eissenberg, Rohde, & Cheskin, 2000) . As a result of the incomplete treatment options for alcohol cessation, research is ongoing to identify new therapies that treat both the cognitive-disruptive and addictive effects of ethanol.
One potential therapeutic target for treating alcoholism is the nicotinic acetylcholinergic system. There are strong correlations between susceptibilities to ethanol and nicotine dependence (Dawson, 2000; John, Meyer, Rumpf, & Hake, 2003) and between heavy consumption of both drugs (Dawson, 2000; John et al., 2003; Larsson & Engel, 2004 ) that may reflect a genetic link between alcoholism and nicotine addiction (Funk, Marinelli, & Le, 2006) . In addition, both ethanol and nicotine act on nicotinic acetylcholine receptors (nAChRs) that underlie diverse neuronal processes (Davis & De Fiebre, 2006) such as those involved in reward/reinforcement (Jerlhag, Grotli, Luthman, Svensson, & Engel, 2006; Walters, Brown, Changeux, Martin, & Damaj, 2006) and learning/memory (Chan, Wong, & Sheu, 2007; Davis, Kenney, & Gould, 2007; Gould, 2006) . Drugs that target nAChRs have been shown to decrease both nicotine consumption (Rollema et al., 2007a; Tennant, Tarver, & Rawson, 1984) and ethanol consumption (Blomqvist, Ericson, Johnson, Engel, & Soderpalm, 1996; Ericson, Blomqvist, Engel, & Soderpalm, 1998; Le, Corrigall, Harding, Juzytsch, & Li, 2000) . Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist and a7 nicotinic receptor full agonist that is currently prescribed as a smoking cessation aid (under the names Chantix or Champix), has recently been shown to decrease ethanol consumption and craving (Steensland, Simms, Holgate, Richards, & Bartlett, 2007) . It remains unclear, however, if varenicline also exerts an effect on ethanol-induced cognitive deficits.
The goal of the current study was to examine the dose-dependent interactive effects of acute varenicline and ethanol on contextual and cued fear conditioning. Fear conditioning is useful for investigating the effects of ethanol on learning because it tests two types of learning that are disrupted by ethanol (Gould, 2003; Gould & Lom- 
